TrialNeuro-oncology2021

Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial.

Zhenzhou Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.